Friday IPO doubleheader from Maze and Metsera brings life to biotech debuts
Obesity drug developer Metsera and kidney disease biotech Maze Therapeutics priced their Nasdaq IPOs on Thursday evening.
Metsera $MTSR will raise $275 million and Maze …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.